關(guān)鍵詞

貝伐珠單抗?端粒 肝細(xì)胞癌?人源化單克隆抗體?色素沉著?硫酰化 衰老

?

#今日行業(yè)熱點(diǎn)#

①The New England Journal of Medicine：Combination Therapy, Including Bevacizumab, for Advanced Colorectal Cancer

臨床試驗(yàn)：貝伐珠單抗（Bevacizumab）聯(lián)合用曲氟尿苷-替吡拉西（Trifluridine–Tipiracil，F(xiàn)TD-TPI）用于難治性轉(zhuǎn)移性結(jié)直腸癌

DOI :10.1056/NEJMe2300385

②The New England Journal of Medicine：Familial Clonal Hematopoiesis in a Long Telomere Syndrome

與長(zhǎng)端粒長(zhǎng)度相關(guān)的POT1突變?cè)黾优c一系列良性和惡性實(shí)體瘤相關(guān)的家族性克隆性造血綜合征的風(fēng)險(xiǎn)

DOI :10.1056/NEJMoa2300503

③Pharmacological Research：Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex

整合素亞基β5（ITGB5）誘導(dǎo)的CSNK1A1上調(diào)通過破壞EPS15/EGFR復(fù)合物，降低肝細(xì)胞癌（HCC）細(xì)胞對(duì)多靶點(diǎn)酪氨酸激酶抑制劑（TKIs）索拉非尼的敏感性

DOI :10.1016/j.phrs.2023.106789

④Clinical Immunology：Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s

抗C1s人源化單克隆抗體SAR445088：一種針對(duì)C1s活性形式的經(jīng)典途徑補(bǔ)體抑制劑

DOI :10.1016/j.clim.2023.109629

⑤Clinical Immunology：Dark pigmentation and related low FMOD expression increase IL-3 and facilitate plasmacytoid dendritic cell maturation

產(chǎn)生色素的黑素細(xì)胞通過色素沉著和相關(guān)的FMOD低表達(dá)增加IL-3，有助于微環(huán)境中的局部免疫調(diào)節(jié)

DOI :10.1016/j.clim.2023.109638

⑥Pharmacological Research：S-sulfhydration of SIRT3 combats BMSC senescence and ameliorates osteoporosis via stabilizing heterochromatic and mitochondrial homeostasis

SIRT3的S-硫?；?/span>通過抑制骨髓間充質(zhì)干細(xì)胞（BMSCs）衰老來改善骨質(zhì)流失

DOI :10.1016/j.phrs.2023.106788

⑦ASC10用于呼吸道合胞病毒（RSV）感染的IIa期臨床試驗(yàn)已獲中國(guó)國(guó)家藥品監(jiān)督管理局（NMPA）已批準(zhǔn)

⑧抗CD40激動(dòng)型單克隆抗體BSI-038在臨床前研究中表現(xiàn)優(yōu)秀，相關(guān)數(shù)據(jù)將在美國(guó)PEGS會(huì)議公布

⑨口服激酶抑制劑司美替尼獲中國(guó)國(guó)家藥品監(jiān)督管理局（NMPA）批準(zhǔn)用于3歲及以上伴有叢狀神經(jīng)纖維瘤的I型神經(jīng)纖維瘤病，成為中國(guó)首個(gè)也是唯一一個(gè)該領(lǐng)域的上市藥物

⑩BTK抑制劑Edralbrutinib用于視神經(jīng)脊髓炎譜系疾?。∟MOSD）適應(yīng)癥獲得美國(guó)食品藥品監(jiān)督管理局授予的孤兒藥資格認(rèn)定

?

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！